Abstract: Traditionally low-grade B-cell lymphomas have been excluded from the category of monomorphic posttransplant lymphoproliferative disorders. However, recent reports identified EpsteinBarr virus-positive (EBV + ) extranodal marginal zone lymphomas (MZL), almost exclusively seen in the posttransplant setting. Some reported cases responded to reduced immunosuppression, suggesting that they should be considered as a form of posttransplant lymphoproliferative disorders. We identified 10 cases of EBV + MZL, 9 in extranodal sites and 1 presenting in lymph node. Two cases arose following solid organ transplantation, but other settings included iatrogenic immunosuppression for rheumatoid arthritis (2); prior chemotherapy (2); congenital immune deficiency (1); and increased age (3), as the only potential cause of immune dysfunction. There were 4 males and 6 females; age range 18 to 86. The atypical plasmacytoid and/or monocytoid B cells were positive for EBV in all cases, with either latency I or II in all cases tested. Monotypic light chain expression was shown in all with 6 cases positive for IgG, and 2 for IgM, undetermined in 2. Clonal immunoglobulin gene rearrangement was positive in all cases with successful amplification. MYD88 L265P was wild type in the 6 cases tested. We show that EBV + MZLs can arise in a variety of clinical settings, and are most often extranodal. Treatment varied, but most patients had clinically indolent disease with response to reduction of immune suppression, or immunochemotherapy.
P osttransplantation lymphoproliferative disorders (PTLD) refer to a heterogenous group of lymphoid proliferations associated with immunosuppression following solid organ or hematopoietic stem cell transplantation. The incidence of PTLD among solid organ transplant recipients is variable, between 1% and 20%, with risk in a specific individual determined mainly by patient age, organ type, immunosuppression regimens, and pretransplant Epstein-Barr virus (EBV) status. 1 Most PTLDs are of B-cell origin and EBV-driven, comprising a spectrum of morphologically evolving lesions ranging from infectious mononucleosis-like or plasmacytic hyperplasia-type early lesions, polymorphic PTLD, to monomorphic more aggressive B-cell lymphomas. In addition, it is well established that EBV + B-cell lymphoproliferative disorders clinically and pathologically resembling PTLD may occur in other immunocompromised settings such as immunosenescence due to advanced age, 2 patients receiving immunosuppressive or cytotoxic therapy for autoimmune diseases 3 or malignancy, 4 or individuals with inherited immunodeficiency syndromes. 5 The 2008 World Health Organization (WHO) Tumor Classification specifically excluded low-grade B-cell lymphomas, including marginal zone lymphomas (MZL), from the category of monomorphic PTLD. 6 However, EBV + B-cell lymphomas resembling MZL, particularly extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue type (MALT lymphoma), were recently reported to occur in the posttransplant setting, [7] [8] [9] [10] and rarely in other forms of immunodeficiency. 3, 5, 11 Some of the reported EBV + MALT lymphoma cases responded to reduced immunosuppression, highlighting the need to distinguish them from EBV − cases, so that they could be managed properly. Thus, the 2017 revision of the fourth Edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues recognized EBV + extranodal MZL as a rare form of PTLD. 12 We report 10 cases of EBV + MZL, making it the largest series of such cases to date. Nine cases arose in a variety of extranodal sites (MALT lymphoma), while one case was exclusively nodal. Significantly, the clinical settings were diverse, a finding not appreciated in prior reports.
Patients presented following solid organ transplantation, iatrogenic immune suppression, prior multiagent chemotherapy, and with congenital immune deficiency, and advanced age without other cause of immune suppression.
MATERIALS AND METHODS

Selection of Cases
The pathology archives of 2 pathology departments were searched, and 10 EBV + MZL cases were identified. Slides were reviewed by E.S.J., S.G., W.X., and S.P. Cases resembling polymophic PTLD were excluded based on the presence of necrosis, prominent apoptotic bodies, a large cell or immunoblastic component, and cytologically immature plasmacytoid cells. The clinical history before diagnosis, treatment following diagnosis, and clinical outcome were collected from the original medical record whenever possible, or public birth/death database (if lost to follow-up).
Immunohistochemistry and EBV-encoded Small RNA In Situ Hybridization
Immunohistochemical stains were performed on formalin-fixed, paraffin-embedded tissue sections following routine procedures on a Ventana Benchmark automated stainer (Roche Ventana Medical Systems, Tucson, AZ), using the antibodies against CD20 (L26; Roche Diagnostics), CD3 (2GV6; Ventana), CD79a (SP18; Roche Diagnostics), PAX-5 (SP34; Roche Diagnostics), LMP1 (CS 1-4; Dako), EBNA2 (PE2; Abcam), CD138 (B-838; Roche Diagnostics), kappa (rabbit; Roche Diagnostics), lambda (rabbit; Roche Diagnostics), CD38 (SPC32; Vector), MUM-1 (MRQ-43; Roche Diagnostics), Ki-67 (MIB-1; Dako), IgG (rabbit; Dako), IgM (rabbit; Dako), and IgA (rabbit; Dako). EBV-encoded small RNA (EBER) in situ hybridization was performed as previously described. 13 
Molecular Studies
DNA was extracted from formalin-fixed, paraffinembedded tissue and polymerase chain reaction (PCR) amplified for detection of immunoglobulin gene (IGH and IGκ loci) rearrangements (8 cases), and MYD88 gene mutation (6 cases). For the IGH locus, 2 separate reactions were performed, the first using consensus primers to framework region III and the joining region of the immunoglobulin heavy chain gene (FRIII-IGH PCR), and the second using consensus primers to framework region II and the joining region of the immunoglobulin heavy chain gene (FRII-IGH PCR), as described by Ramasamy et al. 14 For both reactions the joining region primer was covalently linked to a fluorescent dye FAM to allow for fluorescence detection. The products were analyzed by capillary electrophoresis on an ABI 3130xl Genetic Analyzer, and electropherograms were analyzed using GeneMapper software version 4.0 (ABI). Two additional reactions were performed for the IGκ locus using the BIOMED-2 primer set described by van Dongen et al, 15 and supplied by InVivoScribe Technologies (IGK Gene Clonality Assay-ABI Fluorescence Detection). These reactions interrogate rearrangements involving the Vκ loci and Jκ (Tube A), the Vκ locus and the κDE locus (Tube B), and the κ intron RSS locus and the κDE locus (Tube B). The products were analyzed by capillary electrophoresis on an ABI 3130xl Genetic Analyzer, and electropherograms were analyzed using GeneMapper software version 4.0 (ABI).
For detection of the lymphoid malignancyassociated MYD88 (c.794T > C; p.L265P) mutation, the DNA was subjected to a mutant allele enrichment PCR technique using a single primer set encompassing codon 265 of the MYD88 gene. 16 Enrichment of the mutant allele is achieved through the addition of a modified oligonucleotide (containing several bridged nucleic acids) to the PCR reaction that reduces the amplification efficiency of the normal allele as compared with mutant sequences that may be present. The product was then subjected to pyrosequencing on a Qiagen PyroMark Q24 system.
RESULTS
Clinical Findings Clinical Presentation and Risk Factors
The 10 patients included 4 males and 6 females (ages 18 to 86 y, Table 1 ). Patient 1 (18-y-old female) was the only patient diagnosed with nodal disease. She had received a heart/kidney combined transplant for mitochondrial complex IV deficiency 7 years before her presentation with inguinal lymphadenopathy. All other patients presented with extranodal MALT lymphomas, 4 involving skin or subcutaneous tissue, with other sites being parotid gland (3 cases), lung (1 case), and breast (1 case).
The clinical settings and underlying risk factors varied. A second patient with PTLD (case 7) was status post liver transplant for Wilson disease, and 7 years later developed multiple lesions in the right breast. Two patients had a history of rheumatoid arthritis and Sjogren syndrome, and had been treated with methotrexate (plus additionally etanercept and infliximab in 1). Both patients developed lesions associated with the parotid gland (case 9) and periparotid soft tissue (case 5). Two patients (cases 2 and 6) developed EBV + MALT lymphoma involving soft tissue and lung, respectively, following chemotherapy for a malignant diagnosis, classical Hodgkin lymphoma (CHL) in one, and Ewing sarcoma in the second. Three cases (cases 3, 4, and 8) had no underlying risk factors other than age, with presumed immune senescence, presenting with EBV + MALT lymphoma at ages 69, 70, and 86.
Finally, one patient (case 10), had a history of chronic EBV infections, presenting with an EBV + MALT lymphoma of the parotid at age 18. This patient had cartilage hair hypoplasia syndrome, short stature, and lymphopenia of both B and T cells. Genetic testing showed a pathogenic mutation in the RNA Component of Mitochondrial RNA Processing Endoribonuclease (RMRP) gene as a cause of underlying immune deficiency.
Treatment and Clinical Outcome
The 2 patients with EBV + MZL of PTLD type both initially received only reduced immune suppression. Case 1 developed a clonally related PTLD 6 years later with similar histology, which was treated with 6 cycles of rituximab with no subseqent evidence of recurrent disease. The second (case 7) received DA R-EPOCH in 2011 but relapsed in 2015. Immunosuppression was reduced but soon full immunosuppression was reinstituted because she developed graft rejection. She then received 5 cycles of bortezomib and dexamethasone and valganciclovir hydrochloride and showed partial response. The residual mass was resected and she is currently stable.
Patients 3 (70 y male) and 8 (86 y female) were elderly and had no history of immunosuppressive therapy or prior malignancy. They both presented with multiple skin Case 10, the patient with congenital immune deficency, received a stem cell transplant. She has had a complete remission of her EBV-related disease, with reconstitution of immune status.
Morphologic, Immunohistochemical, and Molecular Features
In this case series of EBV + MZL, 9 of 10 patients had extranodal MZL of MALT type, and only 1 patient had nodal MZL ( Table 2 ). The single nodal case (case 1) contained nodular aggregates of monocytoid appearing cells, with round to oval nuclei, finely clumped chromatin, and a rim of pale cytoplasm (Fig. 1) . Normal follicles were absent. The nodules were surrounded by residual paracortical T cells. The atypical cells were positive for CD20, CD79a, showed dim expression of IgGk, and had a low proliferative rate with Ki-67. The cells were only focally positive for CD138 and CD38. EBER positivity Nine extranodal cases all demonstrated more marked plasmacytoid differentiation, generally associated with adjacent areas composed of sheets or aggregates of small lymphocytes (in 6 cases) or monocytoid cells (in 3 cases). Seven of the 9 extranodal cases had a biphasic pattern, with segregation of the plasmacytoid cells from the adjacent small lymphocytic or monocytoid cells (Fig. 2) . However, in 2 of the cases, both of which involved the skin (cases 3, 8) , the plasmacytoid and lymphoid components were more intermixed, with a polymorphous cellular composition (Fig. 3) . None of the cases showed evidence of necrosis or significant apoptotic Case 9 involving the parotid gland showed a slightly different pattern, and was composed of nodules and sheets of monocytoid cells, adjacent to an infiltrate of cells with marked plasmacytic differentiation (Fig. 4) . The monocytoid cells infiltrated the residual ducts, with prominent lymphoepithelial lesions. In contrast to the other extranodal cases, EBER positivity was particularly associated with the monocytoid cells. EBV latency was addressed in 7 of the 10 cases. Two cases contained cells positive for LMP1, while the other cases were negative. All cases studied were negative for EBNA2; no case demonstrated a Latency III phenotype.
All 10 cases demonstrated light chain restriction (6 kappa, 4 lambda). Six cases expressed IgG heavy chain, whereas both cases involving the parotid gland expressed IgM. None of the cases showed staining for IgA. Ki-67 revealed variable proliferation rates from low to moderate.
Immunoglobulin gene rearrangement studies showed clonal peaks in all cases with successful amplification (7 cases); 1 case failed PCR amplification due to poor DNA quality and in 2 cases material for testing was not available. MYD88 gene was wild type in all 6 cases tested.
DISCUSSION
The EBV virus has the potential to transform B cells, and less commonly NK cells and T cells, leading to a broad spectrum of EBV + lymphomas and lymphoproliferative disorders. EBV + B-cell lymphomas are most often high grade, and include EBV + diffuse large B-cell lymphoma, NOS, Burkitt lymphoma, and classical Hodgkin lymphoma, among others. EBV + B-cell lymphomas occur sporadically, but many show greater prevalence in the setting of immune deficiency. EBV + low-grade B-cell lymphomas, in particular, EBV + extranodal MZLs, are rare and were described recently in the posttransplant setting. 8 The revised fourth edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues now recognizes EBV + extranodal MZL as a rare form of PTLD. 12 The report from Gibson and colleagues identified 4 such cases, all of which occurred in the setting of iatrogenic immune suppression following solid organ transplant. All patients presented with subcutaneous nodules, and all expressed IgA. 8 Their review of the literature identified 9 additional cases, all but 2 of which involved cutaneous sites. Two patients presented with EBV + MALT lymphomas of the stomach and small bowel, both arising following kidney transplant. 17, 18 The major differential diagnosis for EBV + MZL in the posttransplant setting is EBV + PTLD, 19 but morphologically similar lesions can be seen in other immune deficiency states. 20 The EBV + MZLs in this series lacked the necrosis and apoptosis that are key features of polymorphic PTLD. While both types of lesions show evidence of plasmacytoid differentiation, the infiltrates in polymorphic PTLD are typically very polymorphic, with a wide range of cellular differentiation. Notably, most of the cases in our series had a biphasic pattern, with the plasmacytoid cells segregated from the other cellular components, monocytoid cells and small lymphocytes. Only 2 cases, both of which involved skin, had a more mixed, polymorphous cellular composition. In those cases showing plasmacytoid differentiation, EBER was most evident in the plasmacytoid component, with the exception of cases 1 and 9, in which the EBER localized to monocytoid cells. Thus, while the dominant population was positive for EBER in all cases, there were admixed B cells present that appeared negative for EBV.
While the histologic appearance may raise a differential diagnosis with polymorphic PTLD, all of the cases studied for EBNA2 were negative. Polymorphic PTLD usually demonstrates a Latency III phenotype (EBNA2 + ). LMP1 was focally positive in 2 of the cases studied (Latency II) but the predominat pattern was Latency I. This profile is helpful in excluding polymorphic PTLD, and is similar to the pattern reported by Gibson et al. 8 Our 22 The last case arose in an 18-y-old female with a pathogenic mutation in RNA Component of Mitochondrial RNA Processing Endoribonuclease (RMRP) gene as a cause of underlying immune deficiency. She had longstanding lymphopenia of both B cells and T cells, as well as evidence of persistent EBV viral infection before the development of an EBV + MALT lymphoma in the parotid gland. Following stem cell transplant, she had reconstitution of immune function and no recurrence of EBVrelated disease. Another report in the literature identified an EBV + MALT lymphoma in the parotid of a patient with ataxia telangiectasia. 5 It is notable that 3 of our cases arose in the parotid gland, the other 2 both in patients with rheumatoid arthritis and Sjogren syndrome. The association of Sjogren syndrome and MALT lymphoma of the salivary gland is well-recognized, 23, 24 but EBV is only rarely studied in this setting. 25 Diss and colleagues using PCR amplification to search for EBV-related sequences found EBV-DNA in 3/ 45 cases of myoepithelial sialadenitis or MALT lymphoma of the salivary gland. However, PCR studies are not able to determine the prevalence and distribution of the EBV + cells. Notably, in our cases, the histological features were not suspicious for an EBV-related lesion, but EBER was strongly and diffusely positive in atypical B cells forming lymphoepithelial lesions within salivary gland ducts. These data warrant further investigation of EBV in MALT lymphomas arising in patients with Sjogren syndrome, especially if they are receiving iatrogenic immune suppression.
Our series also expands the anatomic localization of EBV + MZL. Similar to the report from Gibson and colleagues, skin and subcutaneous tissue were common sites, being involved in 4 of the 10 cases. As noted, 3 cases involved the parotid gland and adjacent soft tissue. Two cases involved the lung and breast, both of which are commonly affected by MALT lymphoma. Notably, one posttransplant case was nodal in origin, a site not previously reported for EBV + MZL. EBV + MZL needs to be distinguished from plasmacytoma, which can occur as a form of PTLD. None of our cases consisted of a pure population of plasma cells, and all had evidence of other B-cell components, either monocytoid cells or small lymphoid cells. CD20 and/or PAX5 were expressed, at least partially in all cases. The prior report from Gibson et al 8 reported expression of IgA in all 4 of their cases. However, we were not able to identify IgA in a single case. Six cases expressed IgG heavy chain, whereas 2 cases involving the parotid gland expressed IgM. In 2 cases the heavy chain class could not be determined. The differential diagnosis also includes lymphoplasmacytic lymphoma. Because of significant plasma cell differentiation seen in 9/10 cases, we performed PCR for evidence of MYD88 L265P mutation. All 6 cases tested exhibited MYD88 in the wild type state.
It has been questioned whether EBV − MALT or nodal MZL might occur with increased incidence in the posttransplant setting or other forms of immune deficiency. [26] [27] [28] [29] Many of these early cases arose in stomach, and often were associated with Helicobacter pylori infection. MZLs also appear to occur in the setting of HIV infection with increased frequency (relative risk, 2.4), and can be seen in both adults and children. 30, 31 The role of immune suppression in the pathogenesis of HIV-associated MZL is uncertain, but may be related to chronic antigenic stimulation. Whether EBV + MZLs are more common than initially expected requires further investigation.
On the basis of the observations in published studies, posttransplant associated EBV + MZLs often respond to reduced immunosuppression. 8, 9, 32 Although we had difficulty in obtaining the details of treatment and clinical outcomes, at least 1 patient (case 1) in our series was treated by reduction in immunosuppression, with initial response. Her EBV + nodal MZL recurred 6 years later, but a complete remission that is maintained to the present time was induced following a course of rituximab. Immunochemotherapy was also employed in some patients, but the addition of chemotherapy may add to immune compromise in this immunosuppressed patient population.
In summary, we report 10 cases of EBV + MZL that arose in various settings of immune compromise. In most of the cases the histological features would not have suggested an EBV-related lesion, and thus the incidence of EBV + MZL may be underestimated in the literature, particularly in the salivary gland where the lesions closely resembled classic EBV − MZL.
